Literature DB >> 21382180

Nontransferrin-bound iron in transfused patients with sickle cell disease.

A Inati1, K M Musallam, M D Cappellini, L Duca, A T Taher.   

Abstract

The value of nontransferrin-bound iron (NTBI) as an index of iron overload in patients with thalassemia has been evaluated; however, data in patients with sickle cell disease (SCD) is limited. NTBI levels were evaluated in a cross-sectional study of 43 transfused patients with SCD. Patient charts were reviewed for demographics, status of the spleen, and total number of lifetime transfusions. All patients were chelation naïve and none of the patients had evidence of hepatitis B or C infection. Blood samples were taken for assessment of NTBI and serum ferritin (SF); liver iron concentration (LIC) was determined by R2 magnetic resonance imaging. NTBI levels were generally low with a median of -0.01 μm (range -2.56 to 6.37 μm). Among study variables, NTBI levels were only significantly correlated to age and total number of lifetime transfusions, whereas LIC and SF only significantly correlated with total number of lifetime transfusions. On multivariate analysis, only total number of lifetime transfusions remained independently correlated with NTBI (P = 0.001), SF (P < 0.001), and LIC (P < 0.001). On multivariate stepwise linear regression analysis, SF was a better predictor of LIC than NTBI. In transfused patients with SCD, NTBI levels are low yet correlate significantly with transfusion burden. However, they offer poor predictability of LIC when compared with SF.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382180     DOI: 10.1111/j.1751-553X.2010.01224.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  4 in total

1.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

2.  Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β-thalassemic mice.

Authors:  Kanokwan Kulprachakarn; Nittaya Chansiw; Kanjana Pangjit; Chada Phisalaphong; Suthat Fucharoen; Robert C Hider; Sineenart Santitherakul; Somdet Srichairatanakool
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

3.  Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Authors:  Elliott Vichinsky; Françoise Bernaudin; Gian Luca Forni; Renee Gardner; Kathryn Hassell; Matthew M Heeney; Baba Inusa; Abdullah Kutlar; Peter Lane; Liesl Mathias; John Porter; Cameron Tebbi; Felicia Wilson; Louis Griffel; Wei Deng; Vanessa Giannone; Thomas Coates
Journal:  Br J Haematol       Date:  2011-05-19       Impact factor: 6.998

4.  Analytical evaluation of serum non-transferrin-bound iron and its relationships with oxidative stress and cardiac load in the general population.

Authors:  Tomonori Sugiura; Yasuaki Dohi; Hiroyuki Takase; Satoshi Fujii; Yoshihiro Seo; Nobuyuki Ohte
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.